X
Takeda proposes selling Shire’s IBD treatment after merger
https://pharmaphorum.com/news/takeda-proposes-selling-shires-ibd-treatment-after-merger/
IBD
FDA approves oral treatment for ulcerative colitis
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.